HFA 24 Late-Breaker Discussion: The TITRATE-HF Study

Published: 15 May 2024

  • Views:

    Views Icon 73
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

HFA 24 - Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) joined onsite by Dr Jasper Brugts (Erasmus University Medical Centre, NL) to discuss the first results from the TITRATE-HF study.

TITRATE-HF is a real-world multicenter longitudinal study which aims to assess drug sequencing strategies for guideline-directed medical therapy (GDMT) initiation in patients with de novo, worsening and chronic heart failure, including dose titration patterns, intolerance for GDMT and the barriers for implementation. 4000 patients with heart failure with reduced ejection fraction (HFrEF) and heart failure with improved ejection fraction (HFimpEF) were enrolled across Dutch centers with a follow-up period of three years.

Findings showed that 44% of patients had received quadruple therapy and 1% received their target dose. The results suggested that it took some time for new drug classes to be implemented well, however, the uptake of SGLT2i seems to be faster than previous drug classes, such as ARNI. In terms of barriers for implementation, the results showed that side effects and intolerances of drugs were relevant as a reason for avoiding guideline directed medical therapies in HFrEF patients.

Recorded onsite at HFA 24, Lisbon.

Support: This is an independent discussion produced by Radcliffe Cardiology.

Editor: Mirjam Boros, Jordan Rance
Video Specialist: Tom Green, Oliver Miles
Interviewer: Jonathan McKenna


You must be to comment. If you are not registered, you can register here.